Alkermes plc (ALKS)
$39.08-1.64%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $6.5B
- Beta
- 0.27
- P/E (TTM)
- 96.97
- Short % float
- 11.57%
- Days to cover
- 6.3
- SI change
- +17.6%
- 1W
- -5.72%
- 1M
- -15.10%
- vs SPY 1W
- -5.58%
- vs SPY 1M
- -17.60%
Industry peers
FMP comparable companies · ranked by market cap
- NBIXSELLNeurocrine Biosciences, Inc.$14.2BRECOVERYQ 16$141.25+0.58%
- JAZZSELLJazz Pharmaceuticals plc$14.0BBEARQ 24$222.45-0.35%
- AXSMSELLAxsome Therapeutics, Inc.$8.8BCRISISQ 34$170.08+3.77%
- ACADSELLAcadia Pharmaceuticals Inc.$3.4BCRISISQ 17$19.58+3.38%
- SUPNSELLSupernus Pharmaceuticals, Inc.$2.4BRECOVERYQ 26$42.14-4.36%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on ALKS?
- LOPJLB’s latest quantitative signal on Alkermes plc (ALKS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ALKS in?
- Alkermes plc (ALKS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Alkermes plc (ALKS) do?
- Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, an…